Cross-validation analysis of the prognostic significance of mucin expression in patients with resected non-small cell lung cancer treated with adjuvant chemotherapy: Results from IALT, JBR.10 and ANITA

Stephen L. Graziano; Benjamin Lacas; Robin Vollmer; Robert Kratzke; Helmut Popper; Martin Filipits; Lesley Seymour; Frances A. Shepherd; Rafael Rosell; Anne Sophie Veillard; Miquel Taron; Jean Pierre Pignon

doi:10.1016/j.lungcan.2013.06.015

Cross-validation analysis of the prognostic significance of mucin expression in patients with resected non-small cell lung cancer treated with adjuvant chemotherapy: Results from IALT, JBR.10 and ANITA

Stephen L. Graziano, Benjamin Lacas, Robin Vollmer, Robert Kratzke, Helmut Popper, Martin Filipits, Lesley Seymour, Frances A. Shepherd, Rafael Rosell, Anne Sophie Veillard, Miquel Taron, Jean Pierre Pignon

Medicine - Hematology, Oncology, Transplant

Research output: Contribution to journal › Article › peer-review

6 Scopus citations

Abstract

Introduction: CALGB 9633 was a randomized trial of observation versus adjuvant chemotherapy for patients with stage IB non-small cell lung cancer (NSCLC). In CALGB 9633, the presence of mucin in the primary tumor was associated with shorter disease-free survival (DFS; hazard ratio (HR). = 1.9, p= 0.002) and overall survival (OS; HR. = 1.9, p= 0.004). Methods: To validate these results, mucin staining was performed on primary tumor specimens from 780 patients treated on IALT, 351 on JBR.10 and 150 on ANITA. The histochemical technique using mucicarmine was performed. The prognostic value of mucin for DFS and OS was tested in a Cox model stratified by trial and adjusted for clinical and pathological factors. A pooled analysis of all 4 trials was performed for the predictive value of mucin for benefit from adjuvant chemotherapy. Results: The cross-validation group had 48% squamous, 37% adenocarcinoma and 15% other NSCLC compared with 29%, 56%, and 15%, respectively in CALGB. Among 1262 patients with assessable results, mucin was positive in IALT 24%, JBR.10 30%, ANITA 22% compared with 45% in CALGB. Histology was the only significant covariate (p<. 0.0001) in multivariate analysis with mucin seen more commonly in adenocarcinoma (56%) compared with squamous (5%) and other NSCLC (15%). Mucin was a borderline negative prognostic factor for DFS (HR. = 1.2 [1.0-1.5], p= 0.06) but not significantly so for OS (HR. = 1.1 [0.9-1.4], p= 0.25). Prognostic value did not vary according to histology: HR. = 1.3 [1.0-1.6] in adenocarcinoma vs. 1.6 [1.2-2.2] for DFS in other histology (interaction p= 0.69). Mucin status was not predictive for benefit from adjuvant chemotherapy (test of interaction: DFS p= 0.27; OS p= 0.49). Conclusions: Mucin was less frequent in the cross-validation group due to its higher percentage of squamous cell carcinomas. The negative impact of mucin was confirmed for DFS but not for OS. Mucin expression was not predictive of overall survival benefit from adjuvant chemotherapy.

Original language	English (US)
Pages (from-to)	149-155
Number of pages	7
Journal	Lung Cancer
Volume	82
Issue number	1
DOIs	https://doi.org/10.1016/j.lungcan.2013.06.015
State	Published - Oct 2013

Bibliographical note

Funding Information:
Dr. Popper has done consulting and received grants from Hoffman LaRoche, Pfizer, Ventana and Boehringer Ingelheim and received royalties from Springer. Dr. Filipits reports honorarium for speaking from Astra Zeneca, Eli Lilly, Merck, Sividon and Abbott. Dr. Pignon has unrestricted grants from Sanofi-Aventis and Roche SA. All others have none declared.

Funding Information:
The research was supported, in part, by grants from the National Cancer Institute ( CA31946 ) to the Cancer and Leukemia Group B (Richard L. Schilsky, MD, Chairman), the CALGB Statistical Center (Stephen George, PhD, CA33601 ), the Canadian Cancer Society, the Ontario Cancer Research Network , Sanofi-Aventis (unrestricted grants) and the Ligue Nationale Contre le Cancer (LNCC) . The content of this manuscript is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute.

Keywords

Adenocarcinoma
Mucin
Non-small cell lung cancer
Predictive factors
Prognostic factors

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access

10.1016/j.lungcan.2013.06.015

OpenUrl availability

Full text

Cite this

Graziano, S. L., Lacas, B., Vollmer, R., Kratzke, R., Popper, H., Filipits, M., Seymour, L., Shepherd, F. A., Rosell, R., Veillard, A. S., Taron, M., & Pignon, J. P. (2013). Cross-validation analysis of the prognostic significance of mucin expression in patients with resected non-small cell lung cancer treated with adjuvant chemotherapy: Results from IALT, JBR.10 and ANITA. Lung Cancer, 82(1), 149-155. https://doi.org/10.1016/j.lungcan.2013.06.015

Cross-validation analysis of the prognostic significance of mucin expression in patients with resected non-small cell lung cancer treated with adjuvant chemotherapy: Results from IALT, JBR.10 and ANITA. / Graziano, Stephen L.; Lacas, Benjamin; Vollmer, Robin et al.
In: Lung Cancer, Vol. 82, No. 1, 10.2013, p. 149-155.

Research output: Contribution to journal › Article › peer-review

Graziano, SL, Lacas, B, Vollmer, R, Kratzke, R, Popper, H, Filipits, M, Seymour, L, Shepherd, FA, Rosell, R, Veillard, AS, Taron, M & Pignon, JP 2013, 'Cross-validation analysis of the prognostic significance of mucin expression in patients with resected non-small cell lung cancer treated with adjuvant chemotherapy: Results from IALT, JBR.10 and ANITA', Lung Cancer, vol. 82, no. 1, pp. 149-155. https://doi.org/10.1016/j.lungcan.2013.06.015

@article{36278898d5f9417783b1212db3808309,

title = "Cross-validation analysis of the prognostic significance of mucin expression in patients with resected non-small cell lung cancer treated with adjuvant chemotherapy: Results from IALT, JBR.10 and ANITA",

abstract = "Introduction: CALGB 9633 was a randomized trial of observation versus adjuvant chemotherapy for patients with stage IB non-small cell lung cancer (NSCLC). In CALGB 9633, the presence of mucin in the primary tumor was associated with shorter disease-free survival (DFS; hazard ratio (HR). = 1.9, p= 0.002) and overall survival (OS; HR. = 1.9, p= 0.004). Methods: To validate these results, mucin staining was performed on primary tumor specimens from 780 patients treated on IALT, 351 on JBR.10 and 150 on ANITA. The histochemical technique using mucicarmine was performed. The prognostic value of mucin for DFS and OS was tested in a Cox model stratified by trial and adjusted for clinical and pathological factors. A pooled analysis of all 4 trials was performed for the predictive value of mucin for benefit from adjuvant chemotherapy. Results: The cross-validation group had 48% squamous, 37% adenocarcinoma and 15% other NSCLC compared with 29%, 56%, and 15%, respectively in CALGB. Among 1262 patients with assessable results, mucin was positive in IALT 24%, JBR.10 30%, ANITA 22% compared with 45% in CALGB. Histology was the only significant covariate (p<. 0.0001) in multivariate analysis with mucin seen more commonly in adenocarcinoma (56%) compared with squamous (5%) and other NSCLC (15%). Mucin was a borderline negative prognostic factor for DFS (HR. = 1.2 [1.0-1.5], p= 0.06) but not significantly so for OS (HR. = 1.1 [0.9-1.4], p= 0.25). Prognostic value did not vary according to histology: HR. = 1.3 [1.0-1.6] in adenocarcinoma vs. 1.6 [1.2-2.2] for DFS in other histology (interaction p= 0.69). Mucin status was not predictive for benefit from adjuvant chemotherapy (test of interaction: DFS p= 0.27; OS p= 0.49). Conclusions: Mucin was less frequent in the cross-validation group due to its higher percentage of squamous cell carcinomas. The negative impact of mucin was confirmed for DFS but not for OS. Mucin expression was not predictive of overall survival benefit from adjuvant chemotherapy.",

keywords = "Adenocarcinoma, Mucin, Non-small cell lung cancer, Predictive factors, Prognostic factors",

author = "Graziano, {Stephen L.} and Benjamin Lacas and Robin Vollmer and Robert Kratzke and Helmut Popper and Martin Filipits and Lesley Seymour and Shepherd, {Frances A.} and Rafael Rosell and Veillard, {Anne Sophie} and Miquel Taron and Pignon, {Jean Pierre}",

note = "Funding Information: Dr. Popper has done consulting and received grants from Hoffman LaRoche, Pfizer, Ventana and Boehringer Ingelheim and received royalties from Springer. Dr. Filipits reports honorarium for speaking from Astra Zeneca, Eli Lilly, Merck, Sividon and Abbott. Dr. Pignon has unrestricted grants from Sanofi-Aventis and Roche SA. All others have none declared. Funding Information: The research was supported, in part, by grants from the National Cancer Institute ( CA31946 ) to the Cancer and Leukemia Group B (Richard L. Schilsky, MD, Chairman), the CALGB Statistical Center (Stephen George, PhD, CA33601 ), the Canadian Cancer Society, the Ontario Cancer Research Network , Sanofi-Aventis (unrestricted grants) and the Ligue Nationale Contre le Cancer (LNCC) . The content of this manuscript is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute.",

year = "2013",

month = oct,

doi = "10.1016/j.lungcan.2013.06.015",

language = "English (US)",

volume = "82",

pages = "149--155",

journal = "Lung Cancer",

issn = "0169-5002",

publisher = "Elsevier Ireland Ltd",

number = "1",

}

TY - JOUR

T1 - Cross-validation analysis of the prognostic significance of mucin expression in patients with resected non-small cell lung cancer treated with adjuvant chemotherapy

T2 - Results from IALT, JBR.10 and ANITA

AU - Graziano, Stephen L.

AU - Lacas, Benjamin

AU - Vollmer, Robin

AU - Kratzke, Robert

AU - Popper, Helmut

AU - Filipits, Martin

AU - Seymour, Lesley

AU - Shepherd, Frances A.

AU - Rosell, Rafael

AU - Veillard, Anne Sophie

AU - Taron, Miquel

AU - Pignon, Jean Pierre

N1 - Funding Information: Dr. Popper has done consulting and received grants from Hoffman LaRoche, Pfizer, Ventana and Boehringer Ingelheim and received royalties from Springer. Dr. Filipits reports honorarium for speaking from Astra Zeneca, Eli Lilly, Merck, Sividon and Abbott. Dr. Pignon has unrestricted grants from Sanofi-Aventis and Roche SA. All others have none declared. Funding Information: The research was supported, in part, by grants from the National Cancer Institute ( CA31946 ) to the Cancer and Leukemia Group B (Richard L. Schilsky, MD, Chairman), the CALGB Statistical Center (Stephen George, PhD, CA33601 ), the Canadian Cancer Society, the Ontario Cancer Research Network , Sanofi-Aventis (unrestricted grants) and the Ligue Nationale Contre le Cancer (LNCC) . The content of this manuscript is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute.

PY - 2013/10

Y1 - 2013/10

N2 - Introduction: CALGB 9633 was a randomized trial of observation versus adjuvant chemotherapy for patients with stage IB non-small cell lung cancer (NSCLC). In CALGB 9633, the presence of mucin in the primary tumor was associated with shorter disease-free survival (DFS; hazard ratio (HR). = 1.9, p= 0.002) and overall survival (OS; HR. = 1.9, p= 0.004). Methods: To validate these results, mucin staining was performed on primary tumor specimens from 780 patients treated on IALT, 351 on JBR.10 and 150 on ANITA. The histochemical technique using mucicarmine was performed. The prognostic value of mucin for DFS and OS was tested in a Cox model stratified by trial and adjusted for clinical and pathological factors. A pooled analysis of all 4 trials was performed for the predictive value of mucin for benefit from adjuvant chemotherapy. Results: The cross-validation group had 48% squamous, 37% adenocarcinoma and 15% other NSCLC compared with 29%, 56%, and 15%, respectively in CALGB. Among 1262 patients with assessable results, mucin was positive in IALT 24%, JBR.10 30%, ANITA 22% compared with 45% in CALGB. Histology was the only significant covariate (p<. 0.0001) in multivariate analysis with mucin seen more commonly in adenocarcinoma (56%) compared with squamous (5%) and other NSCLC (15%). Mucin was a borderline negative prognostic factor for DFS (HR. = 1.2 [1.0-1.5], p= 0.06) but not significantly so for OS (HR. = 1.1 [0.9-1.4], p= 0.25). Prognostic value did not vary according to histology: HR. = 1.3 [1.0-1.6] in adenocarcinoma vs. 1.6 [1.2-2.2] for DFS in other histology (interaction p= 0.69). Mucin status was not predictive for benefit from adjuvant chemotherapy (test of interaction: DFS p= 0.27; OS p= 0.49). Conclusions: Mucin was less frequent in the cross-validation group due to its higher percentage of squamous cell carcinomas. The negative impact of mucin was confirmed for DFS but not for OS. Mucin expression was not predictive of overall survival benefit from adjuvant chemotherapy.

AB - Introduction: CALGB 9633 was a randomized trial of observation versus adjuvant chemotherapy for patients with stage IB non-small cell lung cancer (NSCLC). In CALGB 9633, the presence of mucin in the primary tumor was associated with shorter disease-free survival (DFS; hazard ratio (HR). = 1.9, p= 0.002) and overall survival (OS; HR. = 1.9, p= 0.004). Methods: To validate these results, mucin staining was performed on primary tumor specimens from 780 patients treated on IALT, 351 on JBR.10 and 150 on ANITA. The histochemical technique using mucicarmine was performed. The prognostic value of mucin for DFS and OS was tested in a Cox model stratified by trial and adjusted for clinical and pathological factors. A pooled analysis of all 4 trials was performed for the predictive value of mucin for benefit from adjuvant chemotherapy. Results: The cross-validation group had 48% squamous, 37% adenocarcinoma and 15% other NSCLC compared with 29%, 56%, and 15%, respectively in CALGB. Among 1262 patients with assessable results, mucin was positive in IALT 24%, JBR.10 30%, ANITA 22% compared with 45% in CALGB. Histology was the only significant covariate (p<. 0.0001) in multivariate analysis with mucin seen more commonly in adenocarcinoma (56%) compared with squamous (5%) and other NSCLC (15%). Mucin was a borderline negative prognostic factor for DFS (HR. = 1.2 [1.0-1.5], p= 0.06) but not significantly so for OS (HR. = 1.1 [0.9-1.4], p= 0.25). Prognostic value did not vary according to histology: HR. = 1.3 [1.0-1.6] in adenocarcinoma vs. 1.6 [1.2-2.2] for DFS in other histology (interaction p= 0.69). Mucin status was not predictive for benefit from adjuvant chemotherapy (test of interaction: DFS p= 0.27; OS p= 0.49). Conclusions: Mucin was less frequent in the cross-validation group due to its higher percentage of squamous cell carcinomas. The negative impact of mucin was confirmed for DFS but not for OS. Mucin expression was not predictive of overall survival benefit from adjuvant chemotherapy.

KW - Adenocarcinoma

KW - Mucin

KW - Non-small cell lung cancer

KW - Predictive factors

KW - Prognostic factors

UR - http://www.scopus.com/inward/record.url?scp=84884413545&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884413545&partnerID=8YFLogxK

U2 - 10.1016/j.lungcan.2013.06.015

DO - 10.1016/j.lungcan.2013.06.015

M3 - Article

C2 - 23920379

AN - SCOPUS:84884413545

SN - 0169-5002

VL - 82

SP - 149

EP - 155

JO - Lung Cancer

JF - Lung Cancer

IS - 1

ER -

Cross-validation analysis of the prognostic significance of mucin expression in patients with resected non-small cell lung cancer treated with adjuvant chemotherapy: Results from IALT, JBR.10 and ANITA

Abstract

Bibliographical note

Keywords

UN SDGs

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this